SCHEMBL600673

SCHEMBL600673

Nc1cc(C(F)(F)F)c(Cl)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.49
CA2 P00918 1/20 0.41
CHKA P35790 1/20 0.41
CDK8 P49336 2/20 0.40
NOS3 P29474 1/20 0.39
NOS2 P35228 1/20 0.39
MTOR P42345 8/20 0.39
PIK3CA P42336 7/20 0.39
PIK3C2B O00750 1/20 0.39
PIK3R1 P27986 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
PRKDC P78527 1/20 0.39
RICTOR Q6R327 1/20 0.39
RPTOR Q8N122 1/20 0.39
PIK3C3 Q8NEB9 1/20 0.39
MAPKAP1 Q9BPZ7 1/20 0.39
MLST8 Q9BVC4 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL601414 0.98 PIK3CD (0.47) PIK3CDCA2CHKACDK8NOS3
SCHEMBL22557297 0.83 PIK3CD (0.49) PIK3CDCA2CHKACDK8NOS3
SCHEMBL29975112 0.83 PIK3CD (0.49) PIK3CDCA2CHKACDK8NOS3
SCHEMBL16712832 0.80 CA2 (0.45) PIK3CDCA2CHKANOS3NOS2
SCHEMBL23022443 0.79 NOS3 (0.40) PIK3CDNOS3NOS2PIK3CBKDM4E
SCHEMBL503326 0.79 PIK3CD (0.41) PIK3CDCA2CHKANOS3NOS2
SCHEMBL29498290 0.78 CA2 (0.43) PIK3CDCA2CHKANOS3NOS2
SCHEMBL29435663 0.78 PIK3R1 (0.41) PIK3CDPIK3CAPIK3R1ALDH1A1IDO1
SCHEMBL1515470 0.78 PIK3R1 (0.41) PIK3CDPIK3CAPIK3R1ALDH1A1IDO1
SCHEMBL13274209 0.77 COMT (0.40) PIK3CDALDH1A1SMN1; SMN2IDO1HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118284105-A Composite material, preparation method thereof, light-emitting device and display device TCL科技集团股份有限公司 2024-07-02 CN claimed
US-12257243-B2 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage NOVARTIS AG (CH) 2025-03-25 US disclosed
EP-3632441-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND DAY ONE BIOPHARMACEUTICALS INC (US) 2024-07-17 EP disclosed
CN-118284105-A Composite material, preparation method thereof, light-emitting device and display device TCL科技集团股份有限公司 2024-07-02 CN disclosed
CN-113015735-B 5-Hydroxy-7-oxabicyclo [2.2.1] heptane-2-carboxamide derivatives for inducing chondrogenesis for the treatment of joint damage 诺华股份有限公司 2024-06-21 CN disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 US disclosed
CN-116710453-A Kinase inhibitors and uses thereof 璧辰医药技术股份有限公司 2023-09-05 CN disclosed
EP-3891154-B1 5-HYDROXY-7-OXABICYCLO[2.2.1]HEPTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE NOVARTIS AG (CH) 2023-08-16 EP disclosed
US-7767687-B2 Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors BIOGEN IDEC MA INC. (US) 2010-08-03 US disclosed
WO-2010078408-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2010-07-08 WO disclosed
WO-2010078408-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2010-07-08 WO disclosed
CN-101743242-A Heterocyclic compounds useful as RAF kinase inhibitors BIOGEN IDEC INC 2010-06-16 CN disclosed
US-20090036419-A1 COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2009-02-05 US disclosed
US-20090036419-A1 COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2009-02-05 US disclosed
WO-2009006404-A2 HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2009-01-08 WO disclosed
WO-2009006389-A2 PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2009-01-08 WO disclosed
US-20090005359-A1 Heterocyclic Compounds Useful as RAF Kinase Inhibitors SUNESIS PHARMACEUTICALS, INC (US) 2009-01-01 US disclosed
US-20090005359-A1 Heterocyclic Compounds Useful as RAF Kinase Inhibitors SUNESIS PHARMACEUTICALS, INC (US) 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 PIK3CD 203/4885CA2 2941/4885CHKA 218/4885
US-20090036419-A1 COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF PIK3CD 226/4885CA2 3466/4885CHKA 157/4885
US-12257243-B2 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage COL2A1, COL1A1, FGF1 PIK3CD 1530/4885CA2 1108/4885CHKA 2027/4885
US-20090005359-A1 Heterocyclic Compounds Useful as RAF Kinase Inhibitors BRAF, RAF1, ARAF PIK3CD 255/4885CA2 3813/4885CHKA 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.